Table 2. The market share by number of branded CD4 instruments in 2011, 2012, and 2013 for all responding countries.
| CD4 Platform | CD4 Instrument Brand | WHO PQ Status | 2011 | 2012 | 2013 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Countries Reporting | Number of Reported Instruments | Percentage from Total Number of Reported Instruments | Number of Countries Reporting | Number of Reported Instruments | Percentage from Total Number of Reported Instruments | Number of Countries Reporting | Number of Reported Instruments | Percentage from Total Number of Reported Instruments | |||
| Conventional CD4 | |||||||||||
| BD FACSCount | Yes | 47 | 1,676 | 44.3% | 54 | 1,732 | 39.1% | 48 | 1,937 | 31.6% | |
| CyFlow Counter | No | 32 | 772 | 20.4% | 31 | 782 | 17.7% | 32 | 1,018 | 16.6% | |
| BD FACSCalibur | No | 31 | 416 | 11.0% | 37 | 620 | 14.0% | 33 | 764 | 12.5% | |
| EPICS XL | No | 10 | 122 | 3.2% | 12 | 104 | 2.3% | 16 | 209 | 3.4% | |
| Cytomics FC 500 | No | 0 | 0 | 0.0% | 1 | 1 | 0.02% | 6 | 84 | 1.4% | |
| Millipore Guava | No | 11 | 85 | 2.2% | 14 | 134 | 3.0% | 12 | 125 | 2.0% | |
| DYNAL MB | No | 0 | 0 | 0.0% | 1 | 29 | 0.7% | 1 | 28 | 0.5% | |
| Apogee Auto40 | No | 3 | 4 | 0.1% | 3 | 7 | 0.2% | 9 | 23 | 0.4% | |
| POC CD4 | |||||||||||
| Alere Pima | Yes | 13 | 597 | 15.8% | 23 | 972 | 22.0% | 31 | 1,874 | 30.6% | |
| PointCare NOW | No | 4 | 82 | 2.2% | 6 | 42 | 0.9% | 5 | 39 | 0.6% | |
| CyFlow miniPOC | No | 5 | 31 | 0.8% | 2 | 5 | 0.1% | 4 | 22 | 0.4% | |
PQ, prequalification.